Aditya Birla Sun Life Pharma & Healthcare Fund Regular-Growth
The fund is rated 2 stars. The strongest area was balance between returns and downside risk, while investment selection within each industry provided some support. Investment selection within each asset type did not provide enough support for a higher rating. Higher annual fee of 2.29% was a minor drawback.
This fund has a bad track record with Asset Selection/Timing, a ok track record with Stock Selection/Timing, a good risk-reward ratio. It is important to note, however, that this fund has a 1102.73 AUM and a 2.29 expense ratio. Considering all these factors, we have rated this fund as 2.0 star.
எங்கள் score நீண்டகால performance, risk மற்றும் consistency-ஐ மதிப்பிடுகிறது — past returns மட்டும் அல்ல.
Returns
8 Oct 2026 நிலவரப்படி
Risk ratios
30 Sep 2026 நிலவரப்படி
Portfolio
30 Sep 2026 நிலவரப்படி
Market-cap பிரிவு
துறை ஒதுக்கீடு
Holdings (40)
| Holding | Fund-இன் % | மதிப்பு | பங்குகள் |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd. | 9.28% | ₹99.97 Cr | 2,08,262 |
| Sun Pharmaceutical Industries Ltd. | 8.61% | ₹92.79 Cr | 5,10,815 |
| Apollo Hospitals Enterprise Ltd. | 6.44% | ₹69.35 Cr | 84,936 |
| Cipla Ltd. | 6.38% | ₹68.71 Cr | 5,10,452 |
| Aurobindo Pharma Ltd. | 4.52% | ₹48.7 Cr | 2,91,254 |
| Sai Life Sciences Ltd. | 4.49% | ₹48.36 Cr | 3,17,245 |
| Ajanta Pharma Ltd. | 4.34% | ₹46.82 Cr | 1,29,312 |
| Mankind Pharma Ltd. | 3.62% | ₹38.95 Cr | 1,55,574 |
| Dr. Lal Pathlabs Ltd. | 3.50% | ₹37.77 Cr | 1,90,095 |
| Abbott India Ltd. | 3.25% | ₹35.08 Cr | 12,933 |
Fund விவரங்கள்
Long term capital growth. investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.
Exit load of 1% if redeemed within 30 days.